EDTA chelation reappraisal following new clinical trials and regular use in millions of patients: review of preliminary findings and risk/benefit assessment

螯合疗法 医学 毒性 螯合作用 异型生物质的 临床试验 药理学 随机对照试验 药品 重症监护医学 内科学 化学 生物化学 酶 有机化学 地中海贫血
作者
Tammy Born,Christina Kontoghiorghe,Aspasia Spyrou,Annita Kolnagou,George J. Kontoghiorghes
出处
期刊:Toxicology Mechanisms and Methods [Taylor & Francis]
卷期号:23 (1): 11-17 被引量:39
标识
DOI:10.3109/15376516.2012.730562
摘要

EDTA chelation therapy is regularly used in thousands of patients worldwide. An FDA approval of more than 50 years ago for heavy metal detoxification prompted many physicians to use EDTA as an alternative medicine for many categories of patients. Recently, NIH initiated the so-called Trial to Assess Chelation Therapy (TACT), which has been designed to evaluate whether EDTA and high dose oral vitamins and mineral therapy could offer clinical, quality of life, and economic benefits for patients with a previous myocardial infraction. A 50% reduction of urinary Pb and improvement of systolic blood pressure was observed in 33 cardiovascular patients following 20 iv administrations. In another study involving 15 patients of different categories, EDTA also has been shown to be an effective and nontoxic chelator for the removal of xenobiotic metals such as Pb, Cd, Ni and Al. Administration of iv EDTA on weekly basis appears to be a sufficient and nontoxic protocol for treating patients with suspected overload and toxicity of xenobiotic metals especially Pb and Cd. The causative effect of xenobiotic metals in cancer, cardiovascular, neurodegenerative, renal and other diseases needs further investigation. Similarly, the use of EDTA chelation therapy in other conditions, which are not related to xenobiotic metal toxicity needs further investigation and confirmation of therapeutic use from controlled randomized clinical trials. Metal balance and drug interaction studies are required to clarify the risk/benefit assessment for the long term use of EDTA in patients with excess xenobiotic metal toxicity and in other conditions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xuliangjing发布了新的文献求助10
1秒前
小薯条发布了新的文献求助10
1秒前
可爱的函函的应助被YanJinyu采纳,获得30
1秒前
南瓜在树上完成签到 ,获得积分10
2秒前
Ava的应助被宋嘉新采纳,获得10
2秒前
hongyan完成签到,获得积分10
2秒前
molihuakai的应助被科研小白采纳,获得10
3秒前
4秒前
6秒前
6秒前
7秒前
科研通AI6.4的应助被hongyan采纳,获得10
7秒前
molurenjvb完成签到,获得积分10
7秒前
milai发布了新的文献求助10
7秒前
8秒前
8秒前
9秒前
9秒前
柯楠吴完成签到,获得积分10
9秒前
cbh完成签到,获得积分10
9秒前
绿叶发布了新的文献求助10
9秒前
9秒前
10秒前
大刘发布了新的文献求助10
11秒前
11秒前
kk发布了新的文献求助10
12秒前
坚强飞扬发布了新的文献求助10
12秒前
13秒前
小薯条完成签到,获得积分10
14秒前
14秒前
14秒前
宋嘉新发布了新的文献求助10
14秒前
米缸发布了新的文献求助10
15秒前
15秒前
柯楠吴发布了新的文献求助10
15秒前
宋树立发布了新的文献求助30
15秒前
Lucas的应助被科研通管家采纳,获得10
15秒前
充电宝的应助被科研通管家采纳,获得10
15秒前
15秒前
852的应助被枫叶采纳,获得10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8163643
求助须知:如何正确求助?哪些是违规求助? 9557771
关于积分的说明 21741795
捐赠科研通 7754289
什么是DOI,文献DOI怎么找? 3428316
关于科研通互助平台的介绍 2552989
邀请新用户注册赠送积分活动 2472943